Pharmaceuticals
Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development
- Using Ascletis' proprietary Ultra-Long-Acting Platform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, demonstrated a comparable pharmacokinet...
2025-11-13 07:30
3029
EirGenix Signed The Commercial Licensing Agreement for Its Second HER2 Biosimilar Asset EG1206A
TAIPEI, Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercialization of its independently developed breast cancer biosim...
2025-11-12 20:47
2117
EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A
TAIPEI, Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercialization of its independently developed breast cancer biosim...
2025-11-12 16:12
1549
CureGene Unveils Groundbreaking Preclinical Data for CG-0416, a Novel Oral Non-GLP-1 Therapy, at Obesity Week 2025
CG-0416, a highly liver-targeted THR-β agonist, demonstrates high-quality weight loss by reducing fat mass while preserving muscle, both as a monotherapy and in combination withGLP-1 RAs. ATLANTA, Nov. 11, 2025 /PRNewswire/ -- CureGene Pharmaceuticals ("CureGene") today announced the first discl...
2025-11-12 06:24
2576
OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer
MELBOURNE, Australia and INDIANAPOLIS, Nov. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that final positive results from the Phase 2 OPALESCENCE trial[1] of TLX250-CDx (89 Zr-girentuximab) in metastatic triple negative breast cancer (mTNB...
2025-11-12 04:00
2243
Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments
VALBY, Denmark, Nov. 12, 2025 /PRNewswire/ -- Key highlights Lundbeck's total revenue grew by +14% CER[1] (+13% DKK) to DKK 18,537 million in the first nine months of 2025. Growth in the U.S. andEurope was the driver of this strong performance. * United States: DKK 9,955 million (+22% CER; +19...
2025-11-12 03:11
2342
Mabwell's Novel Anti‑IL‑11 Monoclonal Antibody 9MW3811 Approved by NMPA to Initiate Phase II Clinical Trial in Pathological Scarring
SHANGHAI, Nov. 11, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its novel anti‑IL‑11 monoclonal antibody 9MW3811 has received approval from the China National Medical Products Administration (NMPA) to initiate...
2025-11-11 22:00
3002
Strategic Partnership Between Sanyou Bio and Yugong Bio to Accelerate Expansion in High-End Synthetic Enzyme Market
SHANGHAI, Nov. 11, 2025 /PRNewswire/ -- Sanyou Bio and Yugong Bio today announced the signing of a strategic cooperation agreement. This powerful alliance marks a significant step to deepen their collaboration in the development of high-end synthetic molecular enzymes. This collaboration is base...
2025-11-11 22:00
3646
Guo Guangchang: Fosun Strengthens Globalization Capabilities, Accelerates Innovation through Open Cooperation
HONG KONG, Nov. 11, 2025 /PRNewswire/ -- On 8 November, Guo Guangchang, Chairman of Fosun International, attended the 3rd Pujiang Biopharmaceutical Original Innovation Conference 2025. During the conference, Guo Guangchang stated, "At this crucial juncture today,China's pharmaceutical innovation ...
2025-11-11 15:41
3895
Shilpa Pharma Lifesciences Awarded EcoVadis Gold Medal for Outstanding Sustainability Practices
RAICHUR, India, Nov. 11, 2025 /PRNewswire/ -- Shilpa Pharma Lifesciences Limited, a material subsidiary of Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), has been awarded the prestigiousGold Medal by EcoVadis, the world's most trusted provider of business sustainability ratings. The com...
2025-11-11 09:15
2171
Shilpa Medicare Announces Positive Phase 3 Results for OERIS™ -- A Novel Once-Weekly Ondansetron Extended-Release Injection for Chemotherapy-Induced Nausea and Vomiting (CINV)
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections RAICHUR, India, Nov. 11, 2025 /PRNewswire/ -- Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) announced the successfu...
2025-11-11 09:00
1769
Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B
* Cohort 4 follow-up confirms durable hepatitis B surface antigen (HBsAg) loss at 24 weeks post end of treatment (EOT) in BRII-179 anti-HBs responders treated with elebsiran plus pegylated interferon alfa (PEG-IFNα) * Data suggest the potential to shorten PEG-IFNα treatment duration for BRII-...
2025-11-10 21:30
6384
Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic responses – - A novel mechanism targeting NEK7 and NLRP3 inflammasomes shows promise across multiple myeloid neoplasms – - Preclinical data reveal potential applications in hemolyti...
2025-11-10 21:15
1556
Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage
NANJING, China, Nov. 10, 2025 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study inChina for the treatment of moderate-to-severe atopi...
2025-11-10 20:06
2823
LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis (PSC)
SEOUL, South Korea, Nov. 10, 2025 /PRNewswire/ -- LISCure Biosciences
2025-11-10 20:00
1697
Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer
HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154. This trial is investigating AK154 both as a monotherapy and as a combination with the com...
2025-11-10 19:39
1572
MediTrust Health and Sino Biopharm Sign Strategic Cooperation Agreement at CIIE 2025 to Advance Drug-Insurance Integration New Model
HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Shanghai, November 10, 2025 – During the 8th China International Import Expo (CIIE), Sino Biopharmaceutical Limited ("Sino Biopharm") and Shanghai MediTrust Health Technology Group Co., Ltd. ("M ediTrustHealth") signed a strategic cooperation agreement. The...
2025-11-10 14:18
2216
Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
NEW ORLEANS, Nov. 10, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA. RN0361 achieved potent, durable reductions in ApoC3 and triglycer...
2025-11-10 12:00
2915
Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
CHENGDU, China, Nov. 10, 2025 /PRNewswire/ -- From November 6 to 9, the 2025 Chinese Congress on Holistic Integrative Oncology (CCHIO) was held in Kunming, Yunnan. This conference was jointly organized by the Chinese Anti-Cancer Association (CACA), the Tengchong Science Forum Organizing Committee ...
2025-11-10 10:01
2508
SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly
-Companies will collaborate on RNAi research for metabolic disease targets BOSTON, Nov. 8, 2025 /PRNewswire/ -- SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and Company ("...
2025-11-08 18:00
1963
Week's Top Stories
Most Reposted
Vietnam Explores Sustainable Aviation Fuel Development at International Conference in Hanoi
[Picked up by 301 media titles]
2026-06-25 14:33
IPD and ABB Help Power Sustainable Operations at New Sydney Fish Market
[Picked up by 298 media titles]
2026-06-22 17:40
MetaOptics Begins Shipment of Metalens Smartphone and AI Smart Glasses to European and Japanese Customers for Evaluation
[Picked up by 297 media titles]
2026-06-26 18:11SPHERE AX Partners with U.S. AI Semiconductor Company Blaize at the National Assembly
[Picked up by 293 media titles]
2026-06-24 18:00
BELLUSTAR TOKYO Ranked No. 10 Among Japan's Best City Hotels in Prestigious Award Chosen by Asia-Pacific Travelers
[Picked up by 290 media titles]
2026-06-24 12:00
Most Read
/C O R R E C T I O N -- 707Livescore/
2026-06-20 18:39
4552
Indonesia's Supreme Court Urges Lawyers to Uphold Reason, Instinct, and Conscience Amid Growing Legal Complexity
2026-06-20 01:37
4427
Hong Kong Brings the PUMA HYROX World Championships to the APAC Region for the First Time in 2027
2026-06-20 08:00
3998
Felicitysolar Strengthens Brand Presence at SNEC 2026
2026-06-20 10:44
3722
